Lexicon Pharmaceuticals
LXRX
119 hedge funds and large institutions have $654M invested in Lexicon Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 16 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 25
5% more capital invested
Capital invested by funds: $626M → $654M (+$28.2M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 123 → 119 (-4)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
Top Buyers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$5.04M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$3.77M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 5 |
Renaissance Technologies
New York
|
+$917K |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.84M |
| 2 |
TCT
TIAA CREF Trust
St Louis,
Missouri
|
-$983K |
| 3 |
Morgan Stanley
New York
|
-$715K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$471K |
| 5 |
Two Sigma Investments
New York
|
-$368K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Principal Financial Group
Des Moines,
Iowa
| – | -$55K | -8,559 | Closed |
|
|
RFC
127
Russell Frank Company
Seattle,
Washington
| – | -$49K | -8,043 | Closed |
|
128
Citadel Advisors
Miami,
Florida
| – | -$41K | -6,406 | Closed |
|
|
ICAS
129
Investors Capital Advisory Services
Lynnfield,
Massachusetts
| – | -$15K | -2,429 | Closed |
|
130
Barclays
London,
United Kingdom
| – | -$12.9K | -1,895 | -28% |
|
|
BRWA
131
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$9 | -1,429 | Closed |
|
|
BG
132
BlackRock Group
London,
United Kingdom
| – | -$9K | -1,401 | Closed |
|
|
BBHC
133
Brown Brothers Harriman & Co
New York
| – | -$2K | -317 | Closed |
|
LXRX Hedge Fund Activity: Q1 2015 in Review
119 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2015, worth a combined $654M — up 4.5% from $626M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LXRX and 13 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 40 added.
The largest buyer was Sabby Management, adding an estimated $5.04M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.84M.
- 119 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2015, down from 123 in Q4 2014.
- Funds reported $654M of Lexicon Pharmaceuticals stock for Q1 2015, up 4.5% quarter-over-quarter.
- 13 funds opened new Lexicon Pharmaceuticals positions in Q1 2015 and 16 closed out, a net change of -3 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2015 was Sabby Management, an estimated $5.04M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2015 was T. Rowe Price Associates, an estimated $5.84M sold.
Based on aggregated 13F filings for Q1 2015.